Human Investing LLC Sells 417 Shares of Novo Nordisk A/S (NYSE:NVO)

Human Investing LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,873 shares of the company’s stock after selling 417 shares during the period. Novo Nordisk A/S makes up about 0.5% of Human Investing LLC’s portfolio, making the stock its 26th biggest holding. Human Investing LLC’s holdings in Novo Nordisk A/S were worth $2,723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of NVO. Lebenthal Global Advisors LLC raised its position in Novo Nordisk A/S by 95.7% during the third quarter. Lebenthal Global Advisors LLC now owns 15,603 shares of the company’s stock valued at $1,858,000 after purchasing an additional 7,629 shares in the last quarter. Focus Financial Network Inc. increased its stake in shares of Novo Nordisk A/S by 2.9% in the 3rd quarter. Focus Financial Network Inc. now owns 8,120 shares of the company’s stock valued at $967,000 after purchasing an additional 227 shares during the last quarter. Principal Securities Inc. raised its holdings in shares of Novo Nordisk A/S by 1.7% during the 3rd quarter. Principal Securities Inc. now owns 41,787 shares of the company’s stock worth $4,976,000 after buying an additional 708 shares in the last quarter. Stephens Inc. AR lifted its position in shares of Novo Nordisk A/S by 31.0% during the 3rd quarter. Stephens Inc. AR now owns 158,881 shares of the company’s stock worth $18,918,000 after buying an additional 37,585 shares during the last quarter. Finally, Norris Perne & French LLP MI boosted its stake in Novo Nordisk A/S by 41.0% in the third quarter. Norris Perne & French LLP MI now owns 2,220 shares of the company’s stock valued at $264,000 after buying an additional 646 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the subject of a number of research reports. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Up 0.3 %

NVO traded up $0.31 during trading on Friday, reaching $112.26. 1,333,050 shares of the stock traded hands, compared to its average volume of 4,348,367. The stock’s 50-day moving average is $124.75 and its 200 day moving average is $130.93. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $503.77 billion, a PE ratio of 38.41, a P/E/G ratio of 1.48 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. Equities analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were given a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s payout ratio is 24.66%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.